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 Clinicians recognize that serum creatinine 
oft en increases in response to the adminis-
tration of medications that block the renin – 
angiotensin system. Th is is oft en a source 
of concern, despite the fact that small-scale 
studies in patients with kidney disease indi-
cate that the magnitude of the initial fall of 
estimated glomerular fi ltration rate (GFR) 
is inversely proportional to the long-term 
slope of GFR decline, 1 and systematic 
reviews demonstrate that a rise in serum 
creatinine of up to 30 % above baseline 
activity and may improve renal vascular 
function. For example, BMS-192364 
and BMS-195270 reduce urinary bladder 
contraction and exert RGS-agonist prop-
erties by increasing the action of GAPs 
on Gq proteins. 15 However, this particular 
class of compounds seems eff ective for 
bladder smooth muscle but not vascular 
smooth muscle. Moreover, RGS4 agonists 
may have unintended consequences in 
vascular function; for example, RGS4 in 
endothelial cells attenuates nitric oxide 
activity and inhibits vascular endothelial 
growth factor (VEGF)-induced angion-
genesis, 16 factors that would probably 
exacerbate renal injury processes. 
 Regardless, the elegant study of  Siedlecki 
 et al. 7 has illuminated an important 
new area in the study of renal vascular 
regulation in which multiple vasoactive 
factors are potentially integrated at the 
subcellular level. RGS proteins represent 
an exciting new target by which renal 
hemodynamics may be physiologically 
fi ne-tuned, and the activity of these may 
be impaired in conditions associated with 
renal vascular abnormalities. 
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 Acute fall in glomerular filtration 
rate with renin – angiotensin 
system inhibition: a biomeasure 
of therapeutic success? 
 Matthew R.  Weir 1 
 Glomerular filtration rate (GFR) acutely declines with the introduction of 
renin – angiotensin system inhibition. This response is functional, not 
anatomical, and varies with volume status. The reduction in GFR with 
renin – angiotensin system inhibition may serve as a biomeasure of 
future therapeutic benefit. 
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levels is of no clinical concern as long as 
serum electrolytes remain within normal 
limits. 2 Moreover, clinical studies demon-
strate that any change in renal function or 
serum electrolytes is immediately revers-
ible with cessation of the medication. 3 
Clinical trial data also demonstrate that 
medications that block the renin – angio-
tensin system attenuate the rate of pro-
gression of kidney disease and improve 
survival in patients with diabetes, and 
that patients with higher serum creatinine 
levels derive greater cardiovascular bene fi t 
and greater reduction of the risk of 
renal progression with renin – angiotensin 
system inhibition. 4 – 7  
 Th e new contribution of Holtkamp and 
colleagues 8 (this issue) is very important. 
Not only do their results echo those of a 
smaller study that the same investigators 
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performed several years ago, 1 but they 
importantly add to our understanding of 
how best to interpret the acute change in 
estimated GFR, not only as a biomeasure 
of therapeutic success, but also as an 
important means of interpreting the 
results of clinical trials and the infl uence 
of diff erent types of medications on the 
change in GFR. 
 In this important  post hoc analysis of the 
Reduction of Endpoints in Non-Insulin-
Dependent Diabetes Mellitus with the 
Angiotensin II Antagonist Losartan 
(RENAAL) trial, Holtkamp  et al. 8 compare 
the long-term estimated GFR slope calcu-
lated from baseline of the study (prior to 
the administration of renin – angiotensin 
system blockade) versus the slope of esti-
mated GFR decline calculated 3 months 
aft er initiation of renin – angiotensin system 
inhibition. Th ey demonstrate that if one 
uses the baseline serum creatinine value, 
then the long-term estimated GFR slope is 
much more negative in the tertile of 
patients with a greater initial fall in esti-
mated GFR in response to renin – angio-
tensin system blockade. On the contrary, 
if the long-term estimated GFR slope is 
calculated starting with the value measured 
3 months aft er initiation of renin – angio-
tensin system inhibition, in fact, the 
patients with the greatest initial fall in GFR 
had a significantly less steep slope of 
decline of kidney function. Th e implica-
tions of these observations are substantial 
and provide important perspective for 
clinicians, not only in terms of how they 
care for their patients, but also with 
regard to how they interpret the results of 
diff erent clinical trials. It is important to 
consider that early functional changes in 
GFR may provide a clue as to the long-term 
anatomical benefi ts of renin – angiotensin 
system inhibition. 
 As  Figure 1 shows, one can then interpret 
the initial change in estimated GFR in 
response to a specific medication as a 
biomeasure of subsequent change in the 
long-term slope of estimated GFR. Con-
sider drug A, perhaps a dihydropyridine 
calcium channel blocker, which is associ-
ated with aff erent glomerular vasodilation, 
resulting in an acute increase in GFR 
( Figure 1 , triangles, solid line). Note that 
the subsequent slope from month 6 is more 
negative than the slope calculated from 
baseline (triangles, dashed line). Compare 
this with drug B (circles, solid line), perhaps 
an angiotensin-converting enzyme inhibi-
tor, with which the fall in estimated GFR 
aft er the fi rst 6 months is associated with a 
less negative slope of GFR, in comparison 
with slope calculation from baseline (cir-
cles, dashed line). In fact, these observa-
tions are nearly identical to the results 
of the African American Study of Kidney 
Disease and Hypertension, in which 
patients were randomized to receive either 
the dihydropyridine calcium channel 
blocker amlodipine or the angiotensin-
converting enzyme inhibitor ramipril dur-
ing the initial phase of the clinical trial. 9 
 Th e results of this secondary analysis 
from the RENAAL trial 8 need to be cau-
tiously interpreted, given that there were 
no measures of change in estimated GFR 
slope prior to the participants ’ entering 
the study. However, with the large number 
of patients in this study, and the almost 
3 years of follow-up, one can reasonably 
assume that the observations are clinically 
valid. As the investigators appropriately 
note in their paper, clinicians should 
always interpret any acute fall in estimated 
GFR in response to renin – angiotensin 
system inhibition cautiously, especially if 
it is more than 30 % , as this may indicate 
volume depletion, clinically signifi cant 
renal artery disease, or possibly coadmin-
istration of other medications that can 
aff ect estimated GFR, such as nonsteroidal 
anti-infl ammatory drugs. 
 In summary, this interesting analysis is 
an important contribution to the literature, 
as it provides more robust data to indicate 
that the initial decline in estimated GFR in 
response to renin – angiotensin system 
inhibition may be an important biomeas-
ure of subsequent therapeutic benefi t, and 
that the timing of the serum creatinine 
measures for slope calculation in clinical 
trials needs to be carefully considered. 
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 Figure 1  |  Illustration of two different patterns of change in estimated GFR, calculated from 
baseline (solid line) versus 6 months (dashed line) for drug A (triangles) versus drug B 
(circles). GFR, glomerular filtration rate. 
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 Erythropoiesis-stimulating agents (ESAs) 
have now been used for about three dec-
ades in chronic kidney disease (CKD) 
patients to treat the symptoms of anemia, 
avoid potentially hazardous blood-prod-
uct transfusions, improve some facets of 
quality of life, and (with less certainty) 
reduce cardiovascular risk. 1 Initial re-
ports of the use of ESAs in patients with 
low(er) hemoglobin levels focused on 
dramatic short-term improvements in 
a plethora of surrogate end points but 
regrettably did not then attempt to focus 
on harder, longer-term outcomes such as 
overall patient survival. For more than 
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 Significant further evidence 
to bolster the link between 
epoetin and strokes in chronic 
kidney disease and cancer 
 David J.  Goldsmith 1 and  Adrian C.  Covic 2 
 Erythropoiesis-stimulating agents (ESAs) have been used for about 
three decades in chronic kidney disease patients to treat the symptoms 
of anemia, avoid potentially hazardous blood-product transfusions, 
improve some facets of quality of life, and reduce cardiovascular risk. 
We review a new article in which this association between stroke and 
ESA use is examined in a different population in a different way, 
but with the same worrying findings as seen in the TREAT study. 
 Kidney International (2011)  80, 237 – 239.  doi: 10.1038/ki.2011.133 
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20 years there was only one direction of 
travel — more ESA use, and higher mean 
hemoglobin levels, 2 fueled by a poor 
evidence base, rather more rigid guide-
line statements than could be justifi ed, 
and a naive faith that in the treatment of 
hemoglobin levels rather than patients, 
good things would happen. 3 Th is was 
augmented by repetitive practice-pattern 
surveys equating higher achieved hemo-
globin levels with better care of patients. 
Th e fact that a patient lies within a guide-
line range, or above or below a guideline 
target, does not mandate better patient-
level outcomes. 
 However, from 2006 – 2007 there were 
ominous warning signs of trouble ahead; 
and it is interesting to see now in retro-
spect how the Correction of Hemoglobin 
and Outcomes in Renal Insufficiency 
(CHOIR) and Cardiovascular Risk Reduc-
tion by Early Anemia Treatment with 
Epoetin Beta (CREATE) publications of 
2006 — showcasing increases in cardiovas-
cular and renal end points, respectively —
 did then quickly lead to a marked 
reduction in ESA usage, ESA dosage, and 
thus achieved hemoglobin levels. 4 Th is 
 ‘ reverse trend ’ was given further momen-
tum by the Trial to Reduce Cardiovascular 
Events With Aranesp Th erapy (TREAT) 
study, published in 2009, which rand-
omized diabetic CKD patients to darbe-
poetin, dosed to maintain hemoglobin of 
13  g / dl, versus placebo / control with lim-
ited darbepoetin therapy, to maintain 
hemoglobin     9  g / dl (for a good review 
of this trial, see Goldsmith and Covic 5 ). 
One of the most alarming outcomes from 
TREAT was the finding that patients 
assigned to active darbepoetin treatment 
had double the risk of stroke when com-
pared with those receiving placebo (153 
total events, 5.0 % versus 2.6 % ). It was now 
clearer than ever, to anyone who was lis-
tening, that the use of ESAs was a fi nely 
nuanced intervention — there was no sur-
vival advantage at all to maintaining a 
significantly higher hemoglobin level, 
while there were excesses of strokes, and 
cancer (only in those with a previous his-
tory of cancer), in the more intensive arm 
of the TREAT study. Most importantly, 
that meant that, overall, the hard end-
point outcomes of a low-intensity, ESA-
light, approach were identical to those of 
a higher-intensity, and expensive, ESA-
reliant approach. 5 
 We need now to remember, though, that 
by the time TREAT was published in 2009, 
the use of ESAs had spread far beyond its 
beginnings in CKD patients to diverse clin-
ical areas such as myelodysplasia, anemia of 
chronic disease,  ‘ heart failure, ’ and cancer-
induced, or chemotherapy-induced, 
anemia. 1 In particular, the use of high-
dose ESA therapy to  ‘ rescue ’ chemother-
apy-induced anemia had become 
signifi cantly more common. 6 Evidence for 
benefi t was, as in the early days of ESA use 
in CKD, confi ned to modest changes in 
quality of life and shorter-term surrogate 
end points. Furthermore, in the rush to 
establish ESAs as standard of care in this 
and other conditions, people discounted 
the possibility that diff erent cancers, and 
diff erent chemotherapy regimens, might 
interact adversely with the use of ESAs. 
Subsequently, excess morbidity and mor-
tality began to be reported in cancer 
patients treated with ESAs. 6 
